<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133912</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-08-370</org_study_id>
    <nct_id>NCT01133912</nct_id>
  </id_info>
  <brief_title>Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)</brief_title>
  <acronym>PGT</acronym>
  <official_title>Phase Ib Study of Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) in Patients With HER2 Positive Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jungsil Ro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives :&#xD;
&#xD;
      1. To evaluate the recommended dose of the combination of paclitaxel, gemcitabine, and&#xD;
      lapatinib (Tykerb®) (PGT) as preoperative chemotherapy in patients with HER2 positive&#xD;
      operable breast cancer&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
        1. To evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of PGT&#xD;
&#xD;
        2. To determine the safety profile&#xD;
&#xD;
        3. To assess pCR in primary tumor and axillary LN&#xD;
&#xD;
        4. To evaluate clinical response rate, disease free survival (DFS), and overall survival&#xD;
           (OS)&#xD;
&#xD;
        5. To assess breast conserving rate after preoperative PGT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unlike adjuvant chemotherapy, primary (preoperative) chemotherapy will shrink tumor and allow&#xD;
      some patients to become candidates for conservative surgery and avoid mastectomy. It also is&#xD;
      an in vivo chemosensitivity test and the result is a predictive marker for clinical outcomes.&#xD;
      Paclitaxel is a highly active antitumor agent that promotes microtubule assembly by binding&#xD;
      to tubulin and inhibiting depolymerization. Paclitaxel has been shown to be an effective&#xD;
      agent in the treatment of breast cancer. Gemcitabine is a cytosine arabinoside prodrug analog&#xD;
      and shows response rates of 15% to 46% as a single agent with very low toxicity. The&#xD;
      combination of gemcitabine and paclitaxel is valuable because of the different mechanisms of&#xD;
      action of each drug and their non-overlapping toxicities. Phase II studies of paclitaxel plus&#xD;
      gemcitabine in anthracycline-pretreated metastatic breast cancer showed good tolerance and&#xD;
      encouraging response rates (40%-55%). Paclitaxel plus gemcitabine combination showed overall&#xD;
      survival benefit compared to paclitaxel alone in patients with metastatic breast cancer in an&#xD;
      interim overall survival report. A phase II study with preoperative paclitaxel and&#xD;
      gemcitabine in stage II/III showed 18 % pCR rate at NCC (ASCO 2007 abstract #11080) In HER2&#xD;
      positive breast cancer, HER2 targeted therapies with trastuzumab and lapatinib have shown&#xD;
      much improved clinical response in palliative setting. It also showed that adding trastuzumab&#xD;
      to sequential paclitaxel and FEC chemotherapy significantly increased pCR (25% vs 66.7%) in&#xD;
      preoperative setting for HER2 positive disease. Recently, paclitaxel, gemcitabine, and&#xD;
      trastuzumab combination (PGH) for 6 cycles in patients with HER2 positive and node positive&#xD;
      operable breast cancer observed a strikingly high pCR rate in both tumor and LN in an interim&#xD;
      analysis of multicenter phase II preoperative study in Korea (28 of 47 (61%)). Lapatinib&#xD;
      (Tykerb®), a dual tyrosine kinase inhibitor of ErbB1 and HER2 signaling pathways and it has&#xD;
      shown to inhibit the growth of HER2 overexpressing breast cancer cells that do not respond to&#xD;
      trastuzumab after long-term conditioning. We will examine the hypothesis that paclitaxel,&#xD;
      gemcitabine, and lapatinib (Tykerb®) (PGT) combination could improve the pathological&#xD;
      complete response rate of HER2 positive breast cancer when applied as a preoperative&#xD;
      chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the recommended dose of the combination of paclitaxel, gemcitabine, and lapatinib (Tykerb®) (PGT) as preoperative chemotherapy in patients with HER2 positive operable breast cancer</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel, gemcitabine, lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel, gemcitabine, lapatinib</intervention_name>
    <description>Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.</description>
    <arm_group_label>paclitaxel, gemcitabine, lapatinib</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>Gemzar</other_name>
    <other_name>Tykerb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed and newly diagnosed operable breast cancer&#xD;
&#xD;
          -  Documented HER2 positive disease : 3+ overexpression by IHC or HER2 gene amplification&#xD;
             by FISH&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Clinical stage II or III operable breast cancer&#xD;
&#xD;
          -  Axillary node positivity determined by cytology&#xD;
&#xD;
          -  No prior hormonal, chemotherapy, or radiotherapy is allowed&#xD;
&#xD;
          -  No breast operation other than biopsy to make diagnosis is allowed&#xD;
&#xD;
          -  Negative urine pregnancy test within 7 days prior to registration in premenopausal&#xD;
             patients&#xD;
&#xD;
          -  Adequate hematopoietic function: Absolute granulocyte count ≥1,500/mm3, platelet&#xD;
             ≥100,000/mm3, hemoglobin ≥10g/mm3&#xD;
&#xD;
          -  Adequate hepatic function: total bilirubin ≤1.5mg/dL, AST/ALT ≤2 x UNL, alkaline&#xD;
             phosphatase ≤2 x UNL&#xD;
&#xD;
          -  Adequate renal function: Serum creatinine ≤1.5mg/dL&#xD;
&#xD;
          -  Adequate cardiac function:&#xD;
&#xD;
               1. Normal or nonspecific EKG taken within 1 month of enrollment&#xD;
&#xD;
               2. LVEF ≥50% by MUGA or echocardiogram taken within 4 weeks of enrollment&#xD;
&#xD;
          -  Ability to understand and comply with protocol during study period&#xD;
&#xD;
          -  Patients should sign a written informed consent before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients who received hormonal, chemotherapy or radiotherapy for breast cancer&#xD;
&#xD;
          -  Patients with bilateral breast cancer&#xD;
&#xD;
          -  Patients who underwent surgery for breast cancer&#xD;
&#xD;
          -  Patients with node-negative stage IIA (T2N0) breast cancer&#xD;
&#xD;
          -  Patients who have history of cancer other than in situ uterine cervix cancer or&#xD;
             nonmelanotic skin cancer&#xD;
&#xD;
          -  Patients with GI tract disease resulting in an inability to take oral medication,&#xD;
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures&#xD;
             affecting absorption, uncontrolled GI disease (e.g., Crohn's disease, ulcerative&#xD;
             colitis)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jungsil Ro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cencer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>January 1, 2012</last_update_submitted>
  <last_update_submitted_qc>January 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Jungsil Ro</investigator_full_name>
    <investigator_title>Chief, Center for Clinical Trials, National Cancer Center, Korea</investigator_title>
  </responsible_party>
  <keyword>Patients with HER2 Positive Operable Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

